Quantcast
Viewing all articles
Browse latest Browse all 614

Xencor Reports Third Quarter 2014 Financial Results (Xencor Inc)

(Source: Xencor Inc) Conference call today at 4:30 p.m. EST MONROVIA, Calif., Nov. 10, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the third quarter ended September 30, 2014 and provided a review of recent business highlights. "Xencor has advanced its pipeline on a number of new fronts over the past few months," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. "Most notably, we regained full control of XmAb®5871, a Phase 2 program...

Viewing all articles
Browse latest Browse all 614

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>